Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1921 1
1927 1
1928 1
1929 1
1947 2
1965 1
1967 2
1971 1
1973 1
1974 1
1976 2
1977 1
1978 1
1987 1
1988 1
1991 1
1992 1
1994 3
1995 2
1996 1
1997 2
1998 1
1999 1
2001 3
2002 1
2003 2
2004 1
2005 2
2006 6
2007 3
2008 13
2009 10
2010 7
2011 5
2012 2
2013 2
2014 6
2015 8
2016 4
2017 4
2018 14
2019 5
2020 8
2021 5
2022 10
2023 10
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Competency-based medical education: theory to practice.
Frank JR, Snell LS, Cate OT, Holmboe ES, Carraccio C, Swing SR, Harris P, Glasgow NJ, Campbell C, Dath D, Harden RM, Iobst W, Long DM, Mungroo R, Richardson DL, Sherbino J, Silver I, Taber S, Talbot M, Harris KA. Frank JR, et al. Among authors: richardson dl. Med Teach. 2010;32(8):638-45. doi: 10.3109/0142159X.2010.501190. Med Teach. 2010. PMID: 20662574
Targeting NaPi2b in ovarian cancer.
Banerjee S, Drapkin R, Richardson DL, Birrer M. Banerjee S, et al. Among authors: richardson dl. Cancer Treat Rev. 2023 Jan;112:102489. doi: 10.1016/j.ctrv.2022.102489. Epub 2022 Nov 14. Cancer Treat Rev. 2023. PMID: 36446254 Free article. Review.
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. Among authors: richardson dl. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. Hardesty MM, et al. Among authors: richardson dl. Gynecol Oncol. 2022 Aug;166(2):219-229. doi: 10.1016/j.ygyno.2022.05.020. Epub 2022 Jun 9. Gynecol Oncol. 2022. PMID: 35690498 Free article. Clinical Trial.
Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Tymon-Rosario J, et al. Among authors: richardson dl. Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):6-14. doi: 10.1097/GCO.0000000000000838. Epub 2022 Dec 8. Curr Opin Obstet Gynecol. 2023. PMID: 36484278 Review.
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O'Malley DM. Richardson DL, et al. Gynecol Oncol. 2024 Jun;185:186-193. doi: 10.1016/j.ygyno.2024.01.045. Epub 2024 Mar 5. Gynecol Oncol. 2024. PMID: 38447347 Free article. Clinical Trial.
Olaparib in the treatment of ovarian cancer.
Washington CR, Richardson DL, Moore KN. Washington CR, et al. Among authors: richardson dl. Future Oncol. 2019 Oct;15(30):3435-3449. doi: 10.2217/fon-2019-0271. Epub 2019 Sep 3. Future Oncol. 2019. PMID: 31478762 Review.
New and Novel Therapies for Gynecologic Cancers.
Richardson DL. Richardson DL. Semin Oncol Nurs. 2019 Apr;35(2):217-219. doi: 10.1016/j.soncn.2019.02.009. Epub 2019 Mar 12. Semin Oncol Nurs. 2019. PMID: 30876683 Review.
148 results